Our Latest Stories
Our Science
August 26, 2025
NANOBODY® Technology Platform
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
82
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
September 4, 2025
Media Update: ERS: new data across Sanofi’s immunology pipeline reinforce leadership in respiratory diseases
September 4, 2025
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
September 3, 2025
Media Update: EADV: Sanofi builds on legacy in immunology with new data highlighting advances in treatment of chronic inflammatory skin diseases
August 29, 2025
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia